Pico IV

Pico IV is a pharmaceutical-grade CBD IV infusion company offering the first sterile, intravenous cannabinoid product designed for direct bloodstream delivery. The company manufactures a water-soluble CBD formulation using patent-pending nano-technology that creates ultra-small particles, enabling near 100% bioavailability compared to oral CBD products. Their approach bypasses digestive processing entirely, delivering faster onset and more consistent results for clients seeking stress relief, sleep support, pain management, and recovery optimization.

The company operates a B2B provider network model, supplying over 1,000 clinics nationwide and internationally through a HIPAA-compliant provider portal. Pico IV handles manufacturing, quality assurance, and clinical support while partner clinics administer infusions in spa-like settings. Each infusion session takes approximately 20 minutes, with recommended frequency of every 2-4 weeks to maintain benefits. The product contains zero THC and uses a blend of five different cannabinoids formulated for an entourage effect.

Pico IV positions itself at the intersection of precision medicine and longevity optimization, targeting busy professionals, athletes, biohackers, and wellness seekers who prioritize efficiency and evidence-based solutions. The company emphasizes pharmaceutical-grade manufacturing standards, third-party lab testing for purity and potency, and FDA-compliant production processes as core credibility markers.